Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Dose Escalation and Expansion Basket Trial of TGD001 in Immune-Mediated TTP and Other Thrombotic Microangiopathies
2025-523802-34-00Phase 2Authorised
- Sponsor
- TargED Biopharmaceuticals
- Start
- Oct 2026
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, single-arm trial of TGD001 in thrombotic thrombocytopenic purpura (TTP) and thrombotic microangiopathies (TMA), sponsored by TargED Biopharmaceuticals. Primary endpoint: Treatment emergent adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
TGD001
03
Conditions
thrombotic thrombocytopenic purpura (TTP)thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2025-523802-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523802-34-00.